Bladeless all-laser cataract surgery offers several advantages

Article

A novel surgical technique using two lasers has been introduced offering several potential advantages for cataract surgery, according to recently published data in the journal Clinical Ophthalmology.

A novel surgical technique using two lasers has been introduced offering several potential advantages for cataract surgery, according to recently published data in the journal Clinical Ophthalmology.

The study, by Dr A. John Kanellopoulos (LaserVision gr Institute, Athens, Greece), examined the safety and efficacy of cataract extraction using a bladeless all-laser technique that combines femtosecond and nanosecond lasers. In this study, a female patient of 57 years of age underwent cataract extraction using the two lasers and standard phacoemulsification.

To perform the corneal incision, capsulorhexis and initial lens fragmentation in each eye, Dr Kanellopoulos used the femtosecond laser. Then he employed the nanosecond laser to enter the 2.8 mm incision, uni-axially, complete the viscoelastic-divided nucleus fragment emulsification and removal in one eye, while the other eye was completed using phacoemulsification.

Both eyes were implanted with a foldable acrylic intraocular lens in the posterior chamber. The perioperative acuity, refraction, keratometry, Scheimpflug tomography, intraocular pressure, endothelial cell counts and total energy used with each laser were analysed.

After 6 months, the patient's corrected distance visual acuity improved from 20/60 and 20/70 pre-op to 20/20 in both eyes. The total intraocular energy used was slightly different, with 2 J being ued by the femtosecond laser in both eyes but 6 J were used by the phacoemulsification device in the right eye and 2.4 J by the nanosecond laser in the left eye. This alternative technique was therefore, deemed to offer several potential advantages, including lower intraocular energy use and elimination of the possibility of corneal thermal injury.

For more detailed information please view the abstract here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.